Plenary Session - inactive due to federal service

Vinay Prasad, MD MPH•soundcloud.com

Dr Prasad currently serves as the Director of the Center for Biologics Evaluation and Resesarch (CBER) at the US FDA. The audio on this platform were posted before my FDA employment and do not necessarily represent the views of the FDA or the United States. This site will be inactive during my federal service. A podcast on medicine, oncology, & health policy. Host: Vinay Prasad, MD MPH from University of California San Francisco. Tweet your feedback to @Plenary_Session or e-mail [email protected]

Follow on

Podcasts are better in Metacast mobile app

Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more

Episodes

1.07 Adjuvant Sunitinib in RCC, future of EBM with Dr. John Mandrola

In this episode we discuss the USA FDA's recent approval of sunitinib as the adjuvant treatment for patients with resected renal cell carcinoma who are at high risk of relapse. We also interview cardiologist Dr. John Mandrola on new directions forward for evidence-based medicine.

Sep 11, 2018•1 hr 3 min

1.06 RELEVANCE, Jenny Gill, and Dr. Catherine Livingston of the Oregon Health Authority

In this episode we break down the RELEVANCE trial published in the New England Journal of Medicine; discuss big data in observational studies with Jenny Gill, MS; and interview Dr. Catherine Livingston of OHSU, an expert in healthcare policy, on her work with the Oregon Health Authority and state Medicaid.

Sep 07, 2018•1 hr 22 min

1.05 Cost and Efficacy of Cancer Drugs, ECHELON-1, Dr. Derrick Tao, and EBM with Dr. Martha Gerrity

In this episode we cover the cost and efficacy of cancer drugs; review ECHELON-1; interview Dr. Derrick Tao of OHSU about his recent Lancet Oncology paper on poor control arms; and discuss evidence-based medicine with EBM expert and internist at OHSU, Dr. Martha Gerrity.

Sep 05, 2018•1 hr 1 min

1.04: Nutritional Epi, Lenvatinib, Nivo and Ipi for Melanoma, and Dr. Avi O'Glasser

This week's episode is on nutritional epidemiology by JPA Ioannidis; lenvatinib for hepatocellular carcinoma; nivolumab and ipilimumab for melanoma; and #medtwitter with Dr. Avi O Glasser from OHSU.

Aug 30, 2018•57 min

1.03: RWE, Right to Try, Talazoparib, Nivolumab, and Dr. Andrae Vandross

We're moving to our new format. We begin with a monologue of the most noteworthy articles in this week's news. We'll be talking about real-world evidence, Right to Try, talazoparib, and the FDA approval for nivolumab in small-cell lung cancer. In the second half of the show, we'll interview Dr. Andrae Vandross, a community oncologist at UCLA Medical Center.

Aug 21, 2018•1 hr 6 min

1.02: HemOnc Fellowship and Hype in Cancer Medicine with Dr. Jeremy Cetnar

In episode 2, we discuss the fellowship program and then take a deep dive into hype surrounding cancer drugs. Our guest is Jeremy Cetnar, MD from Oregon Health & Science University.

Aug 16, 2018•35 min

1.01: Introduction and Dr. Adam Obley

Join us for an introduction to who we are and what our podcast is about, then stick around for a hard-hitting discussion of evidence-based medicine, randomized controlled trials, sham controls, and broad next-generation sequencing in cancer. Our guest is Adam Obley, an Assistant Professor of Medicine at Oregon Health & Science University.

Aug 14, 2018•47 min

← Prev

For the best experience, listen in Metacast app for iOS or Android

Open in Metacast